End-of-day quote
Shanghai S.E.
06:00:00 2024-06-10 pm EDT
|
5-day change
|
1st Jan Change
|
62.97
CNY
|
+1.73%
|
|
+9.30%
|
+51.15%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
12,816
|
13,590
|
8,856
|
18,747
|
27,855
|
-
|
-
|
Enterprise Value (EV)
1 |
12,816
|
13,590
|
8,856
|
18,747
|
27,855
|
27,855
|
27,855
|
P/E ratio
|
-33.9
x
|
755
x
|
65.6
x
|
29.1
x
|
26.9
x
|
21.5
x
|
17.4
x
|
Yield
|
-
|
-
|
-
|
0.96%
|
-
|
-
|
-
|
Capitalization / Revenue
|
22,849
x
|
25.6
x
|
-
|
9.32
x
|
9.41
x
|
7.64
x
|
6.35
x
|
EV / Revenue
|
22,849
x
|
25.6
x
|
-
|
9.32
x
|
9.41
x
|
7.64
x
|
6.35
x
|
EV / EBITDA
|
-
|
-
|
-
|
27
x
|
26.1
x
|
21.1
x
|
17
x
|
EV / FCF
|
-
|
-
|
-
|
30,896,517
x
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
0%
|
-
|
-
|
-
|
Price to Book
|
4.45
x
|
4.57
x
|
-
|
4.69
x
|
5.76
x
|
4.66
x
|
3.77
x
|
Nbr of stocks (in thousands)
|
450,000
|
450,000
|
450,000
|
450,000
|
450,000
|
-
|
-
|
Reference price
2 |
28.48
|
30.20
|
19.68
|
41.66
|
61.90
|
61.90
|
61.90
|
Announcement Date
|
2/25/21
|
2/25/22
|
2/27/23
|
2/23/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
0.5609
|
530.1
|
-
|
2,012
|
2,961
|
3,646
|
4,389
|
EBITDA
1 |
-
|
-
|
-
|
695.4
|
1,066
|
1,318
|
1,642
|
EBIT
1 |
-310.5
|
21.83
|
-
|
660.7
|
1,076
|
1,364
|
1,702
|
Operating Margin
|
-55,348.85%
|
4.12%
|
-
|
32.83%
|
36.36%
|
37.4%
|
38.79%
|
Earnings before Tax (EBT)
1 |
-310.5
|
18.27
|
-
|
659.2
|
1,074
|
1,360
|
1,700
|
Net income
1 |
-310.5
|
18.27
|
133
|
644.9
|
1,037
|
1,298
|
1,598
|
Net margin
|
-55,360.17%
|
3.45%
|
-
|
32.04%
|
35.02%
|
35.62%
|
36.4%
|
EPS
2 |
-0.8400
|
0.0400
|
0.3000
|
1.430
|
2.305
|
2.885
|
3.550
|
Free Cash Flow
|
-
|
-
|
-
|
606.8
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
30.15%
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
87.25%
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
94.09%
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
0.4000
|
-
|
-
|
-
|
Announcement Date
|
2/25/21
|
2/25/22
|
2/27/23
|
2/23/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
607
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-25.3%
|
0.62%
|
-
|
18%
|
21.5%
|
21.8%
|
21.7%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
14.7%
|
20.1%
|
20.5%
|
21.1%
|
Assets
1 |
-
|
-
|
-
|
4,384
|
5,159
|
6,334
|
7,571
|
Book Value Per Share
2 |
6.400
|
6.610
|
-
|
8.890
|
10.80
|
13.30
|
16.40
|
Cash Flow per Share
2 |
-0.4400
|
0.0700
|
-
|
1.500
|
1.930
|
2.520
|
3.110
|
Capex
1 |
-
|
-
|
-
|
67.9
|
87
|
74
|
75
|
Capex / Sales
|
-
|
-
|
-
|
3.37%
|
2.94%
|
2.03%
|
1.71%
|
Announcement Date
|
2/25/21
|
2/25/22
|
2/27/23
|
2/23/24
|
-
|
-
|
-
|
|
1st Jan change
|
Capi.
|
---|
| +48.58% | 3.84B | | +18.77% | 125B | | +14.05% | 108B | | -7.16% | 23.64B | | +3.03% | 22.39B | | -11.23% | 17.78B | | -41.74% | 16.43B | | -13.47% | 16.34B | | +2.23% | 13.56B | | +27.13% | 11.59B |
Bio Therapeutic Drugs
|